APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malignant Mesothelioma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Malignant Mesothelioma Drugs Market Analysis and Forecast 2026-2032

20 December 2025200 pages

Choose your research edition.

Industry ResearchMalignant Mesothelioma Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Mesothelioma Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Malignant Mesothelioma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Mesothelioma Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Mesothelioma Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Malignant Mesothelioma Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Malignant Mesothelioma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Malignant Mesothelioma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Malignant Mesothelioma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Malignant Mesothelioma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Malignant Mesothelioma Drugs include Teva Pharmaceuticals, Sun Pharmaceuticals, Sanofi, Novartis, Merck, Mylan, Roche, Eli Lilly and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Malignant Mesothelioma Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Malignant Mesothelioma Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Malignant Mesothelioma Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Malignant Mesothelioma Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Malignant Mesothelioma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Malignant Mesothelioma Drugs sales, projected growth trends, production technology, application and end-user industry.

Malignant Mesothelioma Drugs Segment by Company

Teva Pharmaceuticals

Sun Pharmaceuticals

Sanofi

Novartis

Merck

Mylan

Roche

Eli Lilly

Pfizer

Fresenius Kabi

AstraZeneca

Polaris Pharmaceuticals

Ono Pharmaceutical

Nichi-Iko Pharmaceutical

MolMed

Kyowa Hakko Kirin

Corden Pharma

Concordia International

Bristol-Myers Squibb

Boehringer Ingelheim GmbH

Malignant Mesothelioma Drugs Segment by Type

Vinorelbine

Cisplatin

Pemetrexed

Carboplatin

Gemcitabine

Others

Malignant Mesothelioma Drugs Segment by Application

Retail Pharmacies

Hospital Pharmacies

Oncology Centers

Others

Malignant Mesothelioma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Malignant Mesothelioma Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Malignant Mesothelioma Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Malignant Mesothelioma Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vinorelbine Major Manufacturers Table 3. Cisplatin Major Manufacturers Table 4. Pemetrexed Major Manufacturers Table 5. Carboplatin Major Manufacturers Table 6. Gemcitabine Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Malignant Mesothelioma Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Retail Pharmacies Major Manufacturers Table 10. Hospital Pharmacies Major Manufacturers Table 11. Oncology Centers Major Manufacturers Table 12. Others Major Manufacturers Table 13. Malignant Mesothelioma Drugs Industry Trends Table 14. Malignant Mesothelioma Drugs Industry Drivers Table 15. Malignant Mesothelioma Drugs Industry Opportunities and Challenges Table 16. Malignant Mesothelioma Drugs Industry Restraints Table 17. Global Malignant Mesothelioma Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Malignant Mesothelioma Drugs Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Malignant Mesothelioma Drugs Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2021-2026) Table 21. Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2027-2032) Table 22. Global Malignant Mesothelioma Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 23. Global Malignant Mesothelioma Drugs Sales by Region (2021-2026) & (K Units) Table 24. Global Malignant Mesothelioma Drugs Sales by Region (2027-2032) & (K Units) Table 25. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2021-2026) Table 26. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2027-2032) Table 27. Global Malignant Mesothelioma Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Malignant Mesothelioma Drugs Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Malignant Mesothelioma Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Malignant Mesothelioma Drugs Sales Market Share by Manufacturers (2021-2026) Table 31. Global Malignant Mesothelioma Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global Malignant Mesothelioma Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Malignant Mesothelioma Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Malignant Mesothelioma Drugs Manufacturers, Product Type & Application Table 35. Global Malignant Mesothelioma Drugs Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Malignant Mesothelioma Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Malignant Mesothelioma Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2026) Table 42. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2027-2032) Table 43. Global Malignant Mesothelioma Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 44. Global Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 45. Global Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 46. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2026) Table 47. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2027-2032) Table 48. Global Malignant Mesothelioma Drugs Price by Type (2021-2026) & (US$/Unit) Table 49. Global Malignant Mesothelioma Drugs Price by Type (2027-2032) & (US$/Unit) Table 50. Global Malignant Mesothelioma Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2026) Table 54. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2027-2032) Table 55. Global Malignant Mesothelioma Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 56. Global Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 57. Global Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2026) Table 59. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2027-2032) Table 60. Global Malignant Mesothelioma Drugs Price by Application (2021-2026) & (US$/Unit) Table 61. Global Malignant Mesothelioma Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. Teva Pharmaceuticals Company Information Table 63. Teva Pharmaceuticals Business Overview Table 64. Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 66. Teva Pharmaceuticals Recent Development Table 67. Sun Pharmaceuticals Company Information Table 68. Sun Pharmaceuticals Business Overview Table 69. Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 71. Sun Pharmaceuticals Recent Development Table 72. Sanofi Company Information Table 73. Sanofi Business Overview Table 74. Sanofi Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Sanofi Malignant Mesothelioma Drugs Product Portfolio Table 76. Sanofi Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Novartis Malignant Mesothelioma Drugs Product Portfolio Table 81. Novartis Recent Development Table 82. Merck Company Information Table 83. Merck Business Overview Table 84. Merck Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Merck Malignant Mesothelioma Drugs Product Portfolio Table 86. Merck Recent Development Table 87. Mylan Company Information Table 88. Mylan Business Overview Table 89. Mylan Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Mylan Malignant Mesothelioma Drugs Product Portfolio Table 91. Mylan Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Roche Malignant Mesothelioma Drugs Product Portfolio Table 96. Roche Recent Development Table 97. Eli Lilly Company Information Table 98. Eli Lilly Business Overview Table 99. Eli Lilly Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Eli Lilly Malignant Mesothelioma Drugs Product Portfolio Table 101. Eli Lilly Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Pfizer Malignant Mesothelioma Drugs Product Portfolio Table 106. Pfizer Recent Development Table 107. Fresenius Kabi Company Information Table 108. Fresenius Kabi Business Overview Table 109. Fresenius Kabi Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio Table 111. Fresenius Kabi Recent Development Table 112. AstraZeneca Company Information Table 113. AstraZeneca Business Overview Table 114. AstraZeneca Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. AstraZeneca Malignant Mesothelioma Drugs Product Portfolio Table 116. AstraZeneca Recent Development Table 117. Polaris Pharmaceuticals Company Information Table 118. Polaris Pharmaceuticals Business Overview Table 119. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 121. Polaris Pharmaceuticals Recent Development Table 122. Ono Pharmaceutical Company Information Table 123. Ono Pharmaceutical Business Overview Table 124. Ono Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 126. Ono Pharmaceutical Recent Development Table 127. Nichi-Iko Pharmaceutical Company Information Table 128. Nichi-Iko Pharmaceutical Business Overview Table 129. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 131. Nichi-Iko Pharmaceutical Recent Development Table 132. MolMed Company Information Table 133. MolMed Business Overview Table 134. MolMed Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. MolMed Malignant Mesothelioma Drugs Product Portfolio Table 136. MolMed Recent Development Table 137. Kyowa Hakko Kirin Company Information Table 138. Kyowa Hakko Kirin Business Overview Table 139. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio Table 141. Kyowa Hakko Kirin Recent Development Table 142. Corden Pharma Company Information Table 143. Corden Pharma Business Overview Table 144. Corden Pharma Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Corden Pharma Malignant Mesothelioma Drugs Product Portfolio Table 146. Corden Pharma Recent Development Table 147. Concordia International Company Information Table 148. Concordia International Business Overview Table 149. Concordia International Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Concordia International Malignant Mesothelioma Drugs Product Portfolio Table 151. Concordia International Recent Development Table 152. Bristol-Myers Squibb Company Information Table 153. Bristol-Myers Squibb Business Overview Table 154. Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio Table 156. Bristol-Myers Squibb Recent Development Table 157. Boehringer Ingelheim GmbH Company Information Table 158. Boehringer Ingelheim GmbH Business Overview Table 159. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio Table 161. Boehringer Ingelheim GmbH Recent Development Table 162. North America Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 163. North America Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 164. North America Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 165. North America Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 166. North America Malignant Mesothelioma Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 167. North America Malignant Mesothelioma Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 168. North America Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 169. North America Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 170. North America Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 171. North America Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 172. North America Malignant Mesothelioma Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 173. North America Malignant Mesothelioma Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 174. North America Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. North America Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. North America Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. North America Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 178. North America Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 179. North America Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 180. North America Malignant Mesothelioma Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 181. North America Malignant Mesothelioma Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 182. United States Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 183. Canada Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 184. Europe Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 185. Europe Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 186. Europe Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 187. Europe Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 188. Europe Malignant Mesothelioma Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 189. Europe Malignant Mesothelioma Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 190. Europe Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 191. Europe Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 192. Europe Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 193. Europe Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 194. Europe Malignant Mesothelioma Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 195. Europe Malignant Mesothelioma Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Europe Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Europe Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Europe Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Europe Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 200. Europe Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 201. Europe Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 202. Europe Malignant Mesothelioma Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 203. Europe Malignant Mesothelioma Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 204. Germany Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 205. France Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 206. U.K. Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 207. Italy Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 208. Netherlands Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 209. Nordic Countries Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 210. China Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 211. China Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 212. China Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 213. China Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 214. China Malignant Mesothelioma Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 215. China Malignant Mesothelioma Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 216. China Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 217. China Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 218. China Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 219. China Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 220. China Malignant Mesothelioma Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 221. China Malignant Mesothelioma Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 222. Asia Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 223. Asia Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 224. Asia Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 225. Asia Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 226. Asia Malignant Mesothelioma Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 227. Asia Malignant Mesothelioma Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 228. Asia Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 229. Asia Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 230. Asia Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 231. Asia Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 232. Asia Malignant Mesothelioma Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 233. Asia Malignant Mesothelioma Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 234. Asia Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 235. Asia Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 236. Asia Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 237. Asia Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 238. Asia Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 239. Asia Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 240. Asia Malignant Mesothelioma Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 241. Asia Malignant Mesothelioma Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 242. Japan Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 243. South Korea Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 244. India Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 245. Australia Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 246. China Taiwan Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 247. Southeast Asia Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 248. SAMEA Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 249. SAMEA Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 250. SAMEA Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 251. SAMEA Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 252. SAMEA Malignant Mesothelioma Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 253. SAMEA Malignant Mesothelioma Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 254. SAMEA Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 255. SAMEA Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 256. SAMEA Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 257. SAMEA Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 258. SAMEA Malignant Mesothelioma Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 259. SAMEA Malignant Mesothelioma Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 260. SAMEA Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 261. SAMEA Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 262. SAMEA Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 263. SAMEA Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 264. SAMEA Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 265. SAMEA Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 266. SAMEA Malignant Mesothelioma Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 267. SAMEA Malignant Mesothelioma Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 268. Brazil Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 269. Argentina Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 270. Chile Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 271. Colombia Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 272. Peru Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 273. Saudi Arabia Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 274. Israel Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 275. UAE Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 276. Turkey Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 277. Iran Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 278. Egypt Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Table 279. Key Raw Materials Table 280. Raw Materials Key Suppliers Table 281. Malignant Mesothelioma Drugs Distributors List Table 282. Malignant Mesothelioma Drugs Customers List Table 283. Research Programs/Design for This Report Table 284. Authors List of This Report Table 285. Secondary Sources Table 286. Primary Sources List of Figures Figure 1. Malignant Mesothelioma Drugs Image Figure 2. Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Mesothelioma Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vinorelbine Image Figure 5. Cisplatin Image Figure 6. Pemetrexed Image Figure 7. Carboplatin Image Figure 8. Gemcitabine Image Figure 9. Others Image Figure 10. Global Malignant Mesothelioma Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Malignant Mesothelioma Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 12. Retail Pharmacies Image Figure 13. Hospital Pharmacies Image Figure 14. Oncology Centers Image Figure 15. Others Image Figure 16. Global Malignant Mesothelioma Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Figure 18. Global Malignant Mesothelioma Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Malignant Mesothelioma Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2021-2032) Figure 21. Global Malignant Mesothelioma Drugs Sales (2021-2032) & (K Units) Figure 22. Global Malignant Mesothelioma Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 23. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Malignant Mesothelioma Drugs Sales YoY (2021-2032) & (K Units) Figure 25. Europe Malignant Mesothelioma Drugs Sales YoY (2021-2032) & (K Units) Figure 26. China Malignant Mesothelioma Drugs Sales YoY (2021-2032) & (K Units) Figure 27. Asia (Excluding China) Malignant Mesothelioma Drugs Sales YoY (2021-2032) & (K Units) Figure 28. South America, Middle East and Africa Malignant Mesothelioma Drugs Sales YoY (2021-2032) & (K Units) Figure 29. Global Malignant Mesothelioma Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Malignant Mesothelioma Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Malignant Mesothelioma Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Malignant Mesothelioma Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2032) Figure 35. Global Malignant Mesothelioma Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Malignant Mesothelioma Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2032) Figure 38. Global Malignant Mesothelioma Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Malignant Mesothelioma Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2032) Figure 41. Global Malignant Mesothelioma Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 42. Global Malignant Mesothelioma Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2032) Figure 44. North America Malignant Mesothelioma Drugs Revenue Share by Type (2021-2032) Figure 45. North America Malignant Mesothelioma Drugs Sales Share by Type (2021-2032) Figure 46. North America Malignant Mesothelioma Drugs Revenue Share by Application (2021-2032) Figure 47. North America Malignant Mesothelioma Drugs Sales Share by Application (2021-2032) Figure 48. North America Malignant Mesothelioma Drugs Revenue Share by Country (2021-2032) Figure 49. North America Malignant Mesothelioma Drugs Sales Share by Country (2021-2032) Figure 50. Europe Malignant Mesothelioma Drugs Revenue Share by Type (2021-2032) Figure 51. Europe Malignant Mesothelioma Drugs Sales Share by Type (2021-2032) Figure 52. Europe Malignant Mesothelioma Drugs Revenue Share by Application (2021-2032) Figure 53. Europe Malignant Mesothelioma Drugs Sales Share by Application (2021-2032) Figure 54. Europe Malignant Mesothelioma Drugs Revenue Share by Country (2021-2032) Figure 55. Europe Malignant Mesothelioma Drugs Sales Share by Country (2021-2032) Figure 56. China Malignant Mesothelioma Drugs Revenue Share by Type (2021-2032) Figure 57. China Malignant Mesothelioma Drugs Sales Share by Type (2021-2032) Figure 58. China Malignant Mesothelioma Drugs Revenue Share by Application (2021-2032) Figure 59. China Malignant Mesothelioma Drugs Sales Share by Application (2021-2032) Figure 60. Asia Malignant Mesothelioma Drugs Revenue Share by Type (2021-2032) Figure 61. Asia Malignant Mesothelioma Drugs Sales Share by Type (2021-2032) Figure 62. Asia Malignant Mesothelioma Drugs Revenue Share by Application (2021-2032) Figure 63. Asia Malignant Mesothelioma Drugs Sales Share by Application (2021-2032) Figure 64. Asia Malignant Mesothelioma Drugs Revenue Share by Country (2021-2032) Figure 65. Asia Malignant Mesothelioma Drugs Sales Share by Country (2021-2032) Figure 66. SAMEA Malignant Mesothelioma Drugs Revenue Share by Type (2021-2032) Figure 67. SAMEA Malignant Mesothelioma Drugs Sales Share by Type (2021-2032) Figure 68. SAMEA Malignant Mesothelioma Drugs Revenue Share by Application (2021-2032) Figure 69. SAMEA Malignant Mesothelioma Drugs Sales Share by Application (2021-2032) Figure 70. SAMEA Malignant Mesothelioma Drugs Revenue Share by Country (2021-2032) Figure 71. SAMEA Malignant Mesothelioma Drugs Sales Share by Country (2021-2032) Figure 72. Malignant Mesothelioma Drugs Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Malignant Mesothelioma Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Vinorelbine
  • Cisplatin
  • Pemetrexed
  • Carboplatin
  • Gemcitabine
  • Others
Applications
  • Retail Pharmacies
  • Hospital Pharmacies
  • Oncology Centers
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Sanofi
  • Novartis
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Fresenius Kabi
  • AstraZeneca
  • Polaris Pharmaceuticals
  • Ono Pharmaceutical
  • Nichi-Iko Pharmaceutical
  • MolMed
  • Kyowa Hakko Kirin
  • Corden Pharma
  • Concordia International
  • Bristol-Myers Squibb
  • Boehringer Ingelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Malignant Mesothelioma Drugs Market by Type
  3. 1.2.1 Global Malignant Mesothelioma Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vinorelbine
  5. 1.2.3 Cisplatin
  6. 1.2.4 Pemetrexed
  7. 1.2.5 Carboplatin
  8. 1.2.6 Gemcitabine
  9. 1.2.7 Others
  10. 1.3 Malignant Mesothelioma Drugs Market by Application
  11. 1.3.1 Global Malignant Mesothelioma Drugs Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Retail Pharmacies
  13. 1.3.3 Hospital Pharmacies
  14. 1.3.4 Oncology Centers
  15. 1.3.5 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Malignant Mesothelioma Drugs Market Dynamics
  1. 2.1 Malignant Mesothelioma Drugs Industry Trends
  2. 2.2 Malignant Mesothelioma Drugs Industry Drivers
  3. 2.3 Malignant Mesothelioma Drugs Industry Opportunities and Challenges
  4. 2.4 Malignant Mesothelioma Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Malignant Mesothelioma Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Malignant Mesothelioma Drugs Revenue by Region
  3. 3.2.1 Global Malignant Mesothelioma Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Malignant Mesothelioma Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Malignant Mesothelioma Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Malignant Mesothelioma Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Malignant Mesothelioma Drugs Sales by Region
  9. 3.4.1 Global Malignant Mesothelioma Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Malignant Mesothelioma Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Malignant Mesothelioma Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Malignant Mesothelioma Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Malignant Mesothelioma Drugs Revenue by Manufacturers
  2. 4.1.1 Global Malignant Mesothelioma Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Malignant Mesothelioma Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Malignant Mesothelioma Drugs Sales by Manufacturers
  6. 4.2.1 Global Malignant Mesothelioma Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Malignant Mesothelioma Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Malignant Mesothelioma Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Malignant Mesothelioma Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Malignant Mesothelioma Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Malignant Mesothelioma Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Malignant Mesothelioma Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Malignant Mesothelioma Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Malignant Mesothelioma Drugs Market CR5 and HHI
  16. 4.8.2 2025 Malignant Mesothelioma Drugs Tier 1, Tier 2, and Tier 3
5 Malignant Mesothelioma Drugs Market by Type
  1. 5.1 Global Malignant Mesothelioma Drugs Revenue by Type
  2. 5.1.1 Global Malignant Mesothelioma Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Malignant Mesothelioma Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Malignant Mesothelioma Drugs Sales by Type
  6. 5.2.1 Global Malignant Mesothelioma Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Malignant Mesothelioma Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Malignant Mesothelioma Drugs Price by Type
6 Malignant Mesothelioma Drugs Market by Application
  1. 6.1 Global Malignant Mesothelioma Drugs Revenue by Application
  2. 6.1.1 Global Malignant Mesothelioma Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Malignant Mesothelioma Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Malignant Mesothelioma Drugs Sales by Application
  6. 6.2.1 Global Malignant Mesothelioma Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Malignant Mesothelioma Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Malignant Mesothelioma Drugs Price by Application
7 Company Profiles
  1. 7.1 Teva Pharmaceuticals
  2. 7.1.1 Teva Pharmaceuticals Company Information
  3. 7.1.2 Teva Pharmaceuticals Business Overview
  4. 7.1.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  6. 7.1.5 Teva Pharmaceuticals Recent Developments
  7. 7.2 Sun Pharmaceuticals
  8. 7.2.1 Sun Pharmaceuticals Company Information
  9. 7.2.2 Sun Pharmaceuticals Business Overview
  10. 7.2.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  12. 7.2.5 Sun Pharmaceuticals Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Malignant Mesothelioma Drugs Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Malignant Mesothelioma Drugs Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Merck
  26. 7.5.1 Merck Company Information
  27. 7.5.2 Merck Business Overview
  28. 7.5.3 Merck Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Merck Malignant Mesothelioma Drugs Product Portfolio
  30. 7.5.5 Merck Recent Developments
  31. 7.6 Mylan
  32. 7.6.1 Mylan Company Information
  33. 7.6.2 Mylan Business Overview
  34. 7.6.3 Mylan Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Mylan Malignant Mesothelioma Drugs Product Portfolio
  36. 7.6.5 Mylan Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Roche Malignant Mesothelioma Drugs Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Malignant Mesothelioma Drugs Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Malignant Mesothelioma Drugs Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Fresenius Kabi
  56. 7.10.1 Fresenius Kabi Company Information
  57. 7.10.2 Fresenius Kabi Business Overview
  58. 7.10.3 Fresenius Kabi Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio
  60. 7.10.5 Fresenius Kabi Recent Developments
  61. 7.11 AstraZeneca
  62. 7.11.1 AstraZeneca Company Information
  63. 7.11.2 AstraZeneca Business Overview
  64. 7.11.3 AstraZeneca Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 AstraZeneca Malignant Mesothelioma Drugs Product Portfolio
  66. 7.11.5 AstraZeneca Recent Developments
  67. 7.12 Polaris Pharmaceuticals
  68. 7.12.1 Polaris Pharmaceuticals Company Information
  69. 7.12.2 Polaris Pharmaceuticals Business Overview
  70. 7.12.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  72. 7.12.5 Polaris Pharmaceuticals Recent Developments
  73. 7.13 Ono Pharmaceutical
  74. 7.13.1 Ono Pharmaceutical Company Information
  75. 7.13.2 Ono Pharmaceutical Business Overview
  76. 7.13.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  78. 7.13.5 Ono Pharmaceutical Recent Developments
  79. 7.14 Nichi-Iko Pharmaceutical
  80. 7.14.1 Nichi-Iko Pharmaceutical Company Information
  81. 7.14.2 Nichi-Iko Pharmaceutical Business Overview
  82. 7.14.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  84. 7.14.5 Nichi-Iko Pharmaceutical Recent Developments
  85. 7.15 MolMed
  86. 7.15.1 MolMed Company Information
  87. 7.15.2 MolMed Business Overview
  88. 7.15.3 MolMed Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 MolMed Malignant Mesothelioma Drugs Product Portfolio
  90. 7.15.5 MolMed Recent Developments
  91. 7.16 Kyowa Hakko Kirin
  92. 7.16.1 Kyowa Hakko Kirin Company Information
  93. 7.16.2 Kyowa Hakko Kirin Business Overview
  94. 7.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio
  96. 7.16.5 Kyowa Hakko Kirin Recent Developments
  97. 7.17 Corden Pharma
  98. 7.17.1 Corden Pharma Company Information
  99. 7.17.2 Corden Pharma Business Overview
  100. 7.17.3 Corden Pharma Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Corden Pharma Malignant Mesothelioma Drugs Product Portfolio
  102. 7.17.5 Corden Pharma Recent Developments
  103. 7.18 Concordia International
  104. 7.18.1 Concordia International Company Information
  105. 7.18.2 Concordia International Business Overview
  106. 7.18.3 Concordia International Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Concordia International Malignant Mesothelioma Drugs Product Portfolio
  108. 7.18.5 Concordia International Recent Developments
  109. 7.19 Bristol-Myers Squibb
  110. 7.19.1 Bristol-Myers Squibb Company Information
  111. 7.19.2 Bristol-Myers Squibb Business Overview
  112. 7.19.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio
  114. 7.19.5 Bristol-Myers Squibb Recent Developments
  115. 7.20 Boehringer Ingelheim GmbH
  116. 7.20.1 Boehringer Ingelheim GmbH Company Information
  117. 7.20.2 Boehringer Ingelheim GmbH Business Overview
  118. 7.20.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio
  120. 7.20.5 Boehringer Ingelheim GmbH Recent Developments
8 North America
  1. 8.1 North America Malignant Mesothelioma Drugs Market Size by Type
  2. 8.1.1 North America Malignant Mesothelioma Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Malignant Mesothelioma Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Malignant Mesothelioma Drugs Price by Type (2021-2032)
  5. 8.2 North America Malignant Mesothelioma Drugs Market Size by Application
  6. 8.2.1 North America Malignant Mesothelioma Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Malignant Mesothelioma Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Malignant Mesothelioma Drugs Price by Application (2021-2032)
  9. 8.3 North America Malignant Mesothelioma Drugs Market Size by Country
  10. 8.3.1 North America Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Malignant Mesothelioma Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Malignant Mesothelioma Drugs Market Size by Type
  2. 9.1.1 Europe Malignant Mesothelioma Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Malignant Mesothelioma Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Malignant Mesothelioma Drugs Price by Type (2021-2032)
  5. 9.2 Europe Malignant Mesothelioma Drugs Market Size by Application
  6. 9.2.1 Europe Malignant Mesothelioma Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Malignant Mesothelioma Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Malignant Mesothelioma Drugs Price by Application (2021-2032)
  9. 9.3 Europe Malignant Mesothelioma Drugs Market Size by Country
  10. 9.3.1 Europe Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Malignant Mesothelioma Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Malignant Mesothelioma Drugs Market Size by Type
  2. 10.1.1 China Malignant Mesothelioma Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Malignant Mesothelioma Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Malignant Mesothelioma Drugs Price by Type (2021-2032)
  5. 10.2 China Malignant Mesothelioma Drugs Market Size by Application
  6. 10.2.1 China Malignant Mesothelioma Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Malignant Mesothelioma Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Malignant Mesothelioma Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Malignant Mesothelioma Drugs Market Size by Type
  2. 11.1.1 Asia Malignant Mesothelioma Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Malignant Mesothelioma Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Malignant Mesothelioma Drugs Price by Type (2021-2032)
  5. 11.2 Asia Malignant Mesothelioma Drugs Market Size by Application
  6. 11.2.1 Asia Malignant Mesothelioma Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Malignant Mesothelioma Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Malignant Mesothelioma Drugs Price by Application (2021-2032)
  9. 11.3 Asia Malignant Mesothelioma Drugs Market Size by Country
  10. 11.3.1 Asia Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Malignant Mesothelioma Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Malignant Mesothelioma Drugs Market Size by Type
  2. 12.1.1 SAMEA Malignant Mesothelioma Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Malignant Mesothelioma Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Malignant Mesothelioma Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Malignant Mesothelioma Drugs Market Size by Application
  6. 12.2.1 SAMEA Malignant Mesothelioma Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Malignant Mesothelioma Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Malignant Mesothelioma Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Malignant Mesothelioma Drugs Market Size by Country
  10. 12.3.1 SAMEA Malignant Mesothelioma Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Malignant Mesothelioma Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Malignant Mesothelioma Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Malignant Mesothelioma Drugs Value Chain Analysis
  2. 13.1.1 Malignant Mesothelioma Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Malignant Mesothelioma Drugs Production Mode & Process
  6. 13.2 Malignant Mesothelioma Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Malignant Mesothelioma Drugs Distributors
  9. 13.2.3 Malignant Mesothelioma Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst